Rethinking Cancer Epidemiology, Aging and Machine Learning

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 2142

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Neurosurgery, University Medical School Hospital Erlangen University Hospital (UKER), Friedrich-Alexander University (FAU) Erlangen-Nuremberg, 91054 Erlangen, Germany
2. Department of Public Health Neukölln, District Office Neukölln of Berlin Neukölln, 12359 Berlin, Germany
Interests: epidemiology; socioeconomic factors; brain tumors; microglia; immune system; cognition; children cancer

Special Issue Information

Dear Colleagues,

With increasing life expectancy and aging, cancer control becomes urgent for equitable and optimal health outcomes. To allow all populations to benefit from cancer research, we need to expand cancer surveillance and timely reporting. Thus, artificial intelligence and machine learning can help advance the identification of avoidable and modifiable risk factors and improve tailored cancer therapy. In this Special Issue, we bring bright minds from across various disciplines together to overcome the barriers of cancer. We include health equity, minorities, community partners, and daily practitioners to engage with the integral cancer-health equity in an aging population.

Dr. Nicolai E. Savaskan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer epidemiology
  • aging
  • cancer control
  • artificial intelligence
  • machine learning
  • cancer-health equity

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3693 KiB  
Article
Skin Cancer Recognition Using Unified Deep Convolutional Neural Networks
by Nasser A. AlSadhan, Shatha Ali Alamri, Mohamed Maher Ben Ismail and Ouiem Bchir
Cancers 2024, 16(7), 1246; https://doi.org/10.3390/cancers16071246 - 22 Mar 2024
Cited by 1 | Viewed by 973
Abstract
The incidence of skin cancer is rising globally, posing a significant public health threat. An early and accurate diagnosis is crucial for patient prognoses. However, discriminating between malignant melanoma and benign lesions, such as nevi and keratoses, remains a challenging task due to [...] Read more.
The incidence of skin cancer is rising globally, posing a significant public health threat. An early and accurate diagnosis is crucial for patient prognoses. However, discriminating between malignant melanoma and benign lesions, such as nevi and keratoses, remains a challenging task due to their visual similarities. Image-based recognition systems offer a promising solution to aid dermatologists and potentially reduce unnecessary biopsies. This research investigated the performance of four unified convolutional neural networks, namely, YOLOv3, YOLOv4, YOLOv5, and YOLOv7, in classifying skin lesions. Each model was trained on a benchmark dataset, and the obtained performances were compared based on lesion localization, classification accuracy, and inference time. In particular, YOLOv7 achieved superior performance with an Intersection over Union (IoU) of 86.3%, a mean Average Precision (mAP) of 75.4%, an F1-measure of 80%, and an inference time of 0.32 s per image. These findings demonstrated the potential of YOLOv7 as a valuable tool for aiding dermatologists in early skin cancer diagnosis and potentially reducing unnecessary biopsies. Full article
(This article belongs to the Special Issue Rethinking Cancer Epidemiology, Aging and Machine Learning)
Show Figures

Figure 1

15 pages, 1831 KiB  
Article
Prognostic Factors and Nomogram for Choroid Plexus Tumors: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis
by Abhishek S. Bhutada, Srijan Adhikari, Joshua A. Cuoco, Alexander In, Cara M. Rogers, John A. Jane, Jr. and Eric A. Marvin
Cancers 2024, 16(3), 610; https://doi.org/10.3390/cancers16030610 - 31 Jan 2024
Cited by 1 | Viewed by 769
Abstract
Background: Choroid plexus tumors (CPTs) are rare neoplasms found in the central nervous system, comprising 1% of all brain tumors. These tumors include choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Although gross total resection for choroid [...] Read more.
Background: Choroid plexus tumors (CPTs) are rare neoplasms found in the central nervous system, comprising 1% of all brain tumors. These tumors include choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Although gross total resection for choroid plexus papillomas (CPPs) is associated with long-term survival, there is a scarcity of prospective data concerning the role and sequence of neoadjuvant therapy in treating aCPP and CPC. Methods: From the years 2000 to 2019, 679 patients with CPT were identified from the Surveillance, Epidemiology, and End Result (SEER) database. Among these patients, 456 patients had CPP, 75 patients had aCPP, and 142 patients had CPC. Univariate and multivariable Cox proportional hazard models were run to identify variables that had a significant impact on the primary endpoint of overall survival (OS). A predictive nomogram was built for patients with CPC to predict 5-year and 10-year survival probability. Results: Histology was a significant predictor of OS, with 5-year OS rates of 90, 79, and 61% for CPP, aCPP, and CPC, respectively. Older age and African American race were prognostic for worse OS for patients with CPP. Older age was also associated with reduced OS for patients with aCPP. American Indian/Alaskan Native race was linked to poorer OS for patients with CPC. Overall, treatment with gross total resection or subtotal resection had no difference in OS in patients with CPP or aCPP. Meanwhile, in patients with CPC, gross total resection (GTR) was associated with significantly better OS than subtotal resection (STR) only. However, there is no difference in OS between patients that receive GTR and patients that receive STR with adjuvant therapy. The nomogram for CPC considers types of treatments received. It demonstrates acceptable accuracy in estimating survival probability at 5-year and 10-year intervals, with a C-index of 0.608 (95% CI of 0.446 to 0.77). Conclusions: This is the largest study on CPT to date and highlights the optimal treatment strategies for these rare tumors. Overall, there is no difference in OS with GTR vs. STR in CPP or aCPP. Furthermore, OS is equivalent for CPC with GTR and STR plus adjuvant therapy. Full article
(This article belongs to the Special Issue Rethinking Cancer Epidemiology, Aging and Machine Learning)
Show Figures

Figure 1

Back to TopTop